Erythrodermic psoriasis: pathophysiology and current treatment perspectives

Area of Science:

• Dermatology
• Immunology

Background:

• Erythrodermic psoriasis (EP) is a rare, severe variant of psoriasis vulgaris affecting over 75% of body surface area.
• Its pathogenesis is linked to a T helper 2 (Th2) immune cell phenotype, but remains incompletely understood.
• EP carries significant morbidity and potential mortality, necessitating improved understanding and management.

Purpose of the Study:

• To review the latest therapeutic data for erythrodermic psoriasis.
• To update understanding of EP management strategies.

Main Methods:

• Literature review of recent studies on EP treatment.
• Analysis of efficacy data for emerging and established therapies.

Main Results:

• Cyclosporine and infliximab were previously recommended as first-line therapies for unstable EP.
• Newer biologic agents, including ustekinumab and ixekizumab, show promise.
• Acitretin and methotrexate are options for more stable cases.

Conclusions:

• Current EP management guidelines require updates based on new therapeutic evidence.
• Biologic therapies represent a significant advancement in treating severe erythrodermic psoriasis.
• Further research into EP pathophysiology is crucial for developing targeted treatments.